Beijing Wandong Medical Technology Co (600055) Fair Value & Analysis
Healthcare · CN · Market cap 8.4B CNY
Fair value as of: Aug 6, 2026
From 3 valuation models · updated 4 days ago
Fair value updated Aug 6, 2026, revised from ¥2.27 to ¥2.43 (+7.0%) since Jul 24, 2026. Share price +10.2% over the past month.
Below-average quality, and screening another 79% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥3.82). The favourable scenario is already priced in.
- Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The model range is unusually wide (¥1.18 to ¥3.82). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 6, 2026.
How to read this chart
60‑month range ¥10.10 – ¥34.38 · fair‑value band ¥1.18 – ¥3.82 · the ¥11.51 price screens above the ¥2.43 fair value. Dashed = 300-day average. As of Aug 6, 2026.
Analysis
Beijing Wandong Medical Technology Co (600055) currently trades at ¥11.51, while our model-based Fair Value estimate is ¥2.43, implying the stock looks roughly 78.9% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Beijing Wandong Medical Technology Co generated revenue of 1.4B CNY at a net margin of -20.2%. Revenue grew 8.9% year over year. It earns a return on equity of -5.9%. The balance sheet holds a net cash position of 2.8B CNY. Fundamentals as of Aug 6, 2026
Our scenario range runs from ¥1.18 (bear case) to ¥3.82 (bull case); at ¥11.51, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 39% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -79%, 600055 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Asset-Based (¥4.25) versus Dividend Discount (¥1.83). Highest evidence: Gordon GGM (70).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 6, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 32
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Beijing Wandong Medical Technology Co.,Ltd. engages in the research, development, manufactures, sales, and after-sale services of digital imaging equipment in China. It operates through two segments Medical Equipment Sales Business; and Medical Services and Others.
Full company description
Beijing Wandong Medical Technology Co.,Ltd. engages in the research, development, manufactures, sales, and after-sale services of digital imaging equipment in China. It operates through two segments Medical Equipment Sales Business; and Medical Services and Others. The company provides digital X radiography system (DR), including panorama DR; magnetic resonance imaging system (MRI) for clinical magnetic resonance imaging; X-ray computed tomography system (CT) for clinical X-ray; vascular interventional therapy system (DSA) for clinical examination and interventional treatment of cardiovascular, cerebrovascular, peripheral vascular, and other diseases; flat panel gastrointestinal diagnostic system; digital flat panel breast system; and mobile x-ray machine. The company was formerly known as China Resources Wandong Medical Equipment Co., Ltd. Beijing Wandong Medical Technology Co.,Ltd. company was founded in 1955 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Beijing Wandong Medical Technology Co reported revenue of ¥1.3B in FY2025 versus ¥1.2B in FY2021, a compound +3.8%/yr. Reported net income was −¥228M in FY2025.
600055 screens 79% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Beijing Wandong Medical Technology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Beijing Wandong Medical Technology Co (600055) overvalued or undervalued?
What is the fair value of 600055?
What is the quality score of 600055?
What is the revenue of Beijing Wandong Medical Technology Co (600055)?
What is the net profit margin of 600055?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Beijing Wandong Medical Technology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.